To validate the impact of DOT1L inhibition on enhancing sensitivity to Sorafenib irrespective of MLL-r, we analyzed nine additional MLL wild type samples, including four AML cell lines (Figure S9) and five primary pediatric AML samples (Figure S10). The gene discussed is DOT1L; the disease is acute myeloid leukemia.